Abstract
Background/Aims: Increased parathyroid activity associated with chronic kidney disease is often managed with calcitriol, which can elevate serum calcium (Ca) by increasing bone resorption and intestinal absorption, whereas paricalcitol promotes less bone resorption. This study compared intestinal Ca absorption in hemodialysis patients treated with calcitriol versus paricalcitol (dose ratio 1:3). Methods: Patients (n = 22) aged ≥20 years, on maintenance hemodialysis for ≥2 months with intact parathyroid hormone (iPTH) levels of >200 pg/ml were enrolled in a single-center, double-blind, active-controlled, randomized, crossover trial. Mean fractional intestinal Ca absorption (±SE) was measured by the single-tracer method ( 42Ca) and evaluated with an analysis of variance crossover model. Results: Mean fractional intestinal Ca absorption was significantly lower after paricalcitol (0.135 ± 0.006) versus calcitriol treatment (0.158 ± 0.006, p = 0.022), a 0.023 difference in absolute Ca absorption fraction. Overall Ca absorption was low in the study population, indicating that regulation of Ca absorption may be dysfunctional. There were no significant differences in serum PTH, Ca, phosphorus (P), or Ca × P. Conclusion: Overall, paricalcitol-treated patients absorbed ∼14% less Ca compared with calcitriol-treated patients with similar effects on PTH. In hemodialysis patients, paricalcitol may provide a benefit by lowering the Ca available for removal by dialysis and/or for deposit in bone or soft tissues.
| Original language | English |
|---|---|
| Pages (from-to) | 165-170 |
| Number of pages | 6 |
| Journal | American Journal of Nephrology |
| Volume | 31 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Nephrology
Cite this
Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. / Lund, Richard J.; Andress, Dennis L.; Amdahl, Michael; Williams, Laura A.; Heaney, Robert P.
In: American Journal of Nephrology, Vol. 31, No. 2, 02.2010, p. 165-170.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients
AU - Lund, Richard J.
AU - Andress, Dennis L.
AU - Amdahl, Michael
AU - Williams, Laura A.
AU - Heaney, Robert P.
PY - 2010/2
Y1 - 2010/2
N2 - Background/Aims: Increased parathyroid activity associated with chronic kidney disease is often managed with calcitriol, which can elevate serum calcium (Ca) by increasing bone resorption and intestinal absorption, whereas paricalcitol promotes less bone resorption. This study compared intestinal Ca absorption in hemodialysis patients treated with calcitriol versus paricalcitol (dose ratio 1:3). Methods: Patients (n = 22) aged ≥20 years, on maintenance hemodialysis for ≥2 months with intact parathyroid hormone (iPTH) levels of >200 pg/ml were enrolled in a single-center, double-blind, active-controlled, randomized, crossover trial. Mean fractional intestinal Ca absorption (±SE) was measured by the single-tracer method ( 42Ca) and evaluated with an analysis of variance crossover model. Results: Mean fractional intestinal Ca absorption was significantly lower after paricalcitol (0.135 ± 0.006) versus calcitriol treatment (0.158 ± 0.006, p = 0.022), a 0.023 difference in absolute Ca absorption fraction. Overall Ca absorption was low in the study population, indicating that regulation of Ca absorption may be dysfunctional. There were no significant differences in serum PTH, Ca, phosphorus (P), or Ca × P. Conclusion: Overall, paricalcitol-treated patients absorbed ∼14% less Ca compared with calcitriol-treated patients with similar effects on PTH. In hemodialysis patients, paricalcitol may provide a benefit by lowering the Ca available for removal by dialysis and/or for deposit in bone or soft tissues.
AB - Background/Aims: Increased parathyroid activity associated with chronic kidney disease is often managed with calcitriol, which can elevate serum calcium (Ca) by increasing bone resorption and intestinal absorption, whereas paricalcitol promotes less bone resorption. This study compared intestinal Ca absorption in hemodialysis patients treated with calcitriol versus paricalcitol (dose ratio 1:3). Methods: Patients (n = 22) aged ≥20 years, on maintenance hemodialysis for ≥2 months with intact parathyroid hormone (iPTH) levels of >200 pg/ml were enrolled in a single-center, double-blind, active-controlled, randomized, crossover trial. Mean fractional intestinal Ca absorption (±SE) was measured by the single-tracer method ( 42Ca) and evaluated with an analysis of variance crossover model. Results: Mean fractional intestinal Ca absorption was significantly lower after paricalcitol (0.135 ± 0.006) versus calcitriol treatment (0.158 ± 0.006, p = 0.022), a 0.023 difference in absolute Ca absorption fraction. Overall Ca absorption was low in the study population, indicating that regulation of Ca absorption may be dysfunctional. There were no significant differences in serum PTH, Ca, phosphorus (P), or Ca × P. Conclusion: Overall, paricalcitol-treated patients absorbed ∼14% less Ca compared with calcitriol-treated patients with similar effects on PTH. In hemodialysis patients, paricalcitol may provide a benefit by lowering the Ca available for removal by dialysis and/or for deposit in bone or soft tissues.
UR - http://www.scopus.com/inward/record.url?scp=72049092449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72049092449&partnerID=8YFLogxK
U2 - 10.1159/000266204
DO - 10.1159/000266204
M3 - Article
C2 - 20016142
AN - SCOPUS:72049092449
VL - 31
SP - 165
EP - 170
JO - American Journal of Nephrology
JF - American Journal of Nephrology
SN - 0250-8095
IS - 2
ER -